VRN08 / Voronoi - LARVOL DELTA

Pyramid returns MSP1 inhibitor to Voronoi, ending $846M deal (Bioworld) - "South Korean pharmaceutical Voronoi Inc. said that New Jersey-based Pyramid Biosciences Inc. terminated its previous $846 million deal for Voronoi’s solid and breast cancer drug candidate, VRN-08, in a letter dated Oct. 24, 2023."

Licensing / partnership • Breast Cancer • Oncology • Solid Tumor

Pyramid Biosciences Expands Precision Oncology Pipeline (PRNewswire) - "Pyramid Biosciences...announced the global licensing of the novel monopolar spindle1 (MPS1) called VRN-08 and a second undisclosed asset from Voronoi Inc., a South Korea-based biotechnology company the develops novel kinase inhibitors and target protein degraders. The milestone-based deal is worth up $846 million dollars (USD)....VRN-08 is a potential, best-in-class MPS1 inhibitor with multiple oncology applications including breast cancer, gastrointestinal cancer, small cell lung cancer and others."

Licensing / partnership • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer

[VIRTUAL] VRN08, a Selective Mps1 Kinase Inhibitor Induces Mitotic Catastrophe and Apoptosis Efficiently in Advanced Cancers Including Rb1-Deficient (AACR 2021) - "Especially we confirmed that VRN081569 induces caspase 3/7 activity faster in Rb1-negative cells (~50-fold EC50 of caspase 3/7 activity compared to Rb1-positive cells), and cell cycle analysis has shown that our compound induces a dose-dependent dysregulation of mitosis, resulting in a decrease in the frequency of the G0/G1 phase, and also induces aneuploidy and apoptosis. Finally, we confirmed a combination effects with anti-microtubule agents BCL-2 inhibitor and PARP-1 inhibitor, suggesting that modulation of two different cellular processes may overcome the lack of single agent activity for TNBC."

Late-breaking abstract • Breast Cancer • Eye Cancer • Oncology • Retinoblastoma • Solid Tumor • Triple Negative Breast Cancer • CASP3 • CASP7 • MPS1 • RB1